RxDoctor Payments Data

Carmella Downing, PA

Medical · Carson City, NVNPI 1861647844

Payments from drug & device makers

$1,527in general payments, 2019–2025

Across 49 payments — averaging $31.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scpharmaceuticals Inc.$182
  • E.r. Squibb & Sons, L.L.C.$177
  • Johnson & Johnson$152
  • Pfizer$147
  • AstraZeneca$144
  • Teva Pharmaceuticals USA, Inc.$130
  • plus $595 from 12 others

What the payments were for

  • Food & beverage$1,527100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,527 in reported general payments places this provider in the 60th percentile of 250 medical providers in Nevada.

See all medical providers in Nevada

Medicare billing

Part B allowed, 2024
$100,361
Medicare patients
366
Services billed
1,761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban205$238,697
JardianceEmpagliflozin98$114,502
EntrestoSacubitril/Valsartan70$110,306
XareltoRivaroxaban79$87,225
Spironolactone366$4,335
Torsemide116$3,140
Furosemide378$2,601
Eplerenone26$2,544
Metoprolol Succinate196$2,389
Potassium Chloride76$2,158
Carvedilol237$1,725
Losartan Potassium202$1,718
Bumetanide32$1,429
Amiodarone Hcl69$1,292
Digoxin73$1,257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$147$238,697205 claims
Boehringer IngelheimJardiance$91$114,50298 claims
NovartisEntresto$53$110,30670 claims
Johnson & JohnsonXarelto$152$87,22579 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 250 medical providers in Nevada.

Other medical in Carson City

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →